Sugammadex: Cyclodextrins, development of selective binding agents, pharmacology, clinical development, and future directions

Anesthesiology Clinics

Volumn 28, Issue 4, 2010, Pages 691-708

  Akha, Arezou Sadighi ^a   Rosa, Joseph ^b   Jahr, Jonathan S ^b   Li, Alvin ^a   Kiai, Kianusch ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cyclodextrins; Neuromuscular blocking agents and reversal; Selective binding agents; Sugammadex

Indexed keywords

ATRACURIUM; BENZYLISOQUINOLINE DERIVATIVE; CHOLINESTERASE INHIBITOR; CISATRACURIUM; CURARE; CYCLODEXTRIN; CYCLOPROPANE; MIVACURIUM; MUSCLE RELAXANT AGENT; NEOSTIGMINE; NEUROMUSCULAR BLOCKING AGENT; OPIATE; PANCURONIUM; PHYSOSTIGMINE; PROPOFOL; ROCURONIUM; SEVOFLURANE; SUGAMMADEX; SUXAMETHONIUM; VECURONIUM;

ABDOMEN; ABDOMINAL DISCOMFORT; ABDOMINAL SURGERY; APPENDECTOMY; ARTHRALGIA; BRADYCARDIA; CHILL; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; COUGHING; DELAYED EMERGENCE FROM ANESTHESIA; DIARRHEA; DOSE RESPONSE; DRUG BINDING; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; EMERGENCY MEDICINE; ENDOTRACHEAL INTUBATION; ERYTHEMA; GENERAL ANESTHESIA; HICCUP; HUMAN; HYPERTENSION; HYPOTENSION; INTENSIVE CARE; LIMB PAIN; MOTOR DYSFUNCTION; MUSCLE RELAXATION; MUSCLE TWITCH; NAUSEA; NONHUMAN; OXYGEN DESATURATION; PARASYMPATHETIC TONE; PERITONEAL SURGERY; QT PROLONGATION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TACHYCARDIA; URINE RETENTION; VOMITING;

ANIMALS; CLINICAL TRIALS AS TOPIC; CYCLODEXTRINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG APPROVAL; GAMMA-CYCLODEXTRINS; HUMANS; NEUROMUSCULAR BLOCKADE; NEUROMUSCULAR BLOCKING AGENTS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 78149491589     PISSN: 19322275     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.anclin.2010.08.014     Document Type: Review

References (34)

1. Srivastava A., Hunter J.M. Reversal of NMB. Br J Anaesth 2009, 103(1):115-129.
2. Gray T.C., Halton J. A milestone in anaesthesia? (d-tubocurarine chloride) [section on anaesthetics]. Proc R Soc Med 1946, 39(7):400-408.
3. Naguib M. Sugammadex: another milestone in clinical neuromuscular pharmacology. Anesth Analg 2007, 104(3):575-581.
4. Ren W., Jahr J.S. Reversal of neuromuscular block with a selective relaxant binding agent (SRBA). Am J Ther 2009, 16(4):295-299.
5. Loftsson T., Masson M. Cyclodextrins in topical drug formulations: theory and practice. Int J Pharm 2001, 225(1-2):15-30.
6. Sikharam S., Egan T.D., Kern S.E. Cyclodextrins as new formulation entitles and therapeutic agents. Curr Opin Anaesthesiol 2005, 18(4):392-395.
7. de Boer H.D., van Egmond J., van de Pol F., et al. Chemical encapsulation of rocuronium by synthetic cyclodextrin derivatives: reversal of neuromuscular block in anaesthetized Rhesus monkeys. Br J Anaesth 2005, 96(2):201-206.
8. Wikipedia Cyclodextrin Available at:, Accessed May 2, 2010. http://en.wikipedia.org/wiki/Cyclodextrin.
9. Szente L., Szejtli J. Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development. Adv Drug Deliv Rev 1999, 36(1):17-28.
10. Brewster M.E., Thorsteinn L. Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev 2007, 59:645-666.
11. Wikipedia Selective Relaxant Binding Agents (SRBAs) Available at:, Accessed May 2, 2010. http://en.wikipedia.org/wiki/Selective_Relaxant_Binding_Agent.
12. Adam J.M., Bennett D.J., Bom A., et al. Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships. J Med Chem 2002, 45(9):1806-1816.
13. Miller R. Sugammadex, an opportunity to change the practice of anesthesiology?. Anesth Analg 2007, 104(3):477-478.
14. McDonagh D.L., Benedict P.E., Kovac A.L., et al. Efficacy and safety of sugammadex for reversal of rocuronium induced blockade in elderly patients. Anesthesiology 2007, 107:A1583.
15. Nicholson W.T., Sprung J., Jankowski C.J. Sugammadex: a novel agent for the reversal of neuromuscular blockade. Pharmacotherapy 2007, 27(8):1181-1188.
16. Bom A., Bradley M., Cameron K., et al. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin based synthetic host. Angew Chem Int Ed Engl 2002, 41:266-270.
17. Tarver G.J., Grove S.J.A., Buchanan K., et al. 2- O- substituted cyclodextrins as reversal agents for the neuromuscular blocker rocuronium bromide. Bioorg Med Chem 2002, 10(6):1819-1827.
18. Sorgenfrei I.F., Norrild K., Larsen P.B., et al. Reversal of rocuronium- induced neuromuscular block by the selective relaxant binding agent sugammadex, a dose-finding and safety study. Anesthesiology 2006, 104:667-674.
19. Sandman E., Witt H., Olsson R., et al. The incidence and mechanisms of pharyngeal and upper esophageal dysfunction in partially paralyzed humans: pharyngeal videoradiography and simultaneous manometry after atracurium. Anesthesiology 2000, 92:977-984.
20. Berg H., Viby- Mogensen J., Roed J., et al. Residual neuromuscular block is a risk factor for postoperative pulmonary complications: a prospective, randomized, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Acta Anaesthesiol Scand 1997, 41:1095-1103.
21. Suy K., Morias K., Cammu G., et al. Effective reversal of moderate rocuronium- or vecuronium- induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology 2007, 106:283-288.
22. Lowry D.W., Mirakhur R.K., McCarthy G.J., et al. Neuromuscular effects of rocuronium during sevoflurane, isoflurane, and intravenous anesthesia. Anesth Analg 1998, 87:936-940.
23. Wulf H., Ledowski T., Lindstedt U., et al. Neuromuscular blocking effects of rocuronium during desflurane, isoflurane, and sevoflurane anesthesia. Can J Anaesth 1998, 45:526-532.
24. Vanacker B.F., Vermeyen K.M., Struys M.M., et al. Reversal of rocuronium- induced neuromuscular block with the novel drug sugammadex is equally effective under maintenance anesthesia with propofol or sevoflurane. Anesth Analg 2007, 104:563-568.
25. Groudine S.B., Soto R., Lien C., et al. A randomized, dose- finding, phase II study of the selective relaxant binding drug, sugammadex, capable of safely reversing profound rocuronium- induced neuromuscular block. Anesth Analg 2007, 104:555-562.
26. de Boer H.D., Driessen J.J., Marcus M.A.E., et al. Reversal of rocuronium- induced (1.2 mg/kg) profound neuromuscular block by sugammadex. Anesthesiology 2007, 107:239-244.
27. Duvaldestin P., Kuizenga K., Saldien V., et al. A randomized, dose-response study of sugammadex given for the reversal of deep rocuronium- or vecuronium- induced neuromuscular blockade under sevoflurane anesthesia. Anesth Analg 2010, 110:74-82.
28. Puhringer K., Rex C., Sielenkamper A.W., et al. Reversal of profound, high- dose rocuronium- induced neuromuscular blockade by sugammadex at two different time points. Anesthesiology 2008, 109:188-197.
29. Lee C., Jahr J.S., Candiotti K.A., et al. Reversal of profound neuromuscular block by sugammadex administered three minutes after rocuronium. Anesthesiology 2009, 110:1020-1025.
30. Rex C., Wagner S., Spies C., et al. Reversal of neuromuscular blockade by sugammadex after continuous infusion of rocuronium in patients randomized to sevoflurane or propofol maintenance anesthesia. Anesthesiology 2009, 111:30-35.
31. Briefing Document for the Anesthesia and Life Support Drug Advisory Committee Meeting. Bridion_ NDA 22-225. March 11, 2008. Department of Health & Human Services Food & Drug Administration Center for Drug Evaluation & Research Division of Anesthesia, Analgesia and Rheumatology Products. Available at: Accessed May 16, 2008. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4346b1-01-FDA.pdf.
32. Sugammadex Hypersensitivity Study (Study P06042)(COMPLETED) Jun 10, 2010. Available at: clinicaltrials.gov/ct2/show/NCT00988065. Accessed June 16, 2010.
33. Schering-Plough Corp. Bridion® (sugammadex sodium) injection: first and only selective relaxant binding agent approved in European Union [online]. Available at: Accessed August 20, 2008. http://www.scheringplough.com/schering_plough/news/release.jsp?releaseID=1180933.
34. Soto R., Jahr J., Pavlin J., et al. Safety of sugammadex reversal of rocuronium block vs spontaneous recovery from succinylcholine [abstract] 2010, American Society of Anesthesiologists Anesthesiology 2010. San Diego (CA).